XML 57 R41.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair Value Measurements - Summary of Contingent Consideration Liabilities are Measured at Fair Value Using Significant Unobservable Inputs (Level 3) (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]      
Beginning balance $ 947 $ 947 $ 12,037
Re-measurement of Fair Value 9,198 0 (736)
Settlements of contingent consideration   0 (10,354)
Ending balance 132,284 $ 947 $ 947
ACEA Therapeutics, Inc      
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]      
Contingent consideration related to the acquisition of ACEA Therapeutics, Inc. $ 122,139